Smoke-free products (IQOS, ZYN, VEEV)
Demand Driver
FY2025 revenue growth driven by favorable pricing and higher smoke-free products volume/mix, central to PMI's smoke-free transformation strategy.
Relevance 95·Dependency 75·Confidence 95
Source evidence
“favorable volume/mix, driven by higher smoke-free products volume, notwithstanding unfavorable mix and lower volumes for cigarettes”
IQOS heated tobacco units
Revenue Exposure
HTUs were 155.1 billion equivalent units in 2025, +11.0% vs 2024, and HTU international market share rose to 5.8% — the core smoke-free growth engine.
Relevance 95·Dependency 70·Confidence 95
Source evidence
“SFPHTUOral SFPE-vaporCigarettes”
FDA tobacco regulation
Regulatory Exposure
U.S. business success depends on the evolving FDA framework; IQOS and ZYN authorizations could be withdrawn, particularly if youth or non-nicotine user uptake rises.
Relevance 90·Dependency 70·Confidence 94
Source evidence
“there is no guarantee that the products will remain authorized for sale in the United States, or that new versions of IQOS or other ZYN products will receive authorizations, particularly if there is a significant uptake in youth or non-nicotine user initiation”
Russia
Geopolitical Exposure
PMI has ~$4.8B assets in Russia including $2.3B ruble cash and a 23% stake in distributor Megapolis; developments may cause material adverse impact and impairments.
Relevance 90·Dependency 60·Confidence 95
Source evidence
“These developments above have or may have a material adverse impact on our business, results of operations, cash flows and financial position, and may result in impairment charges.”
Marlboro cigarettes
Revenue Exposure
Marlboro accounted for approximately 43% of total 2025 cigarette shipment volume and its cigarette market share rose to 10.7%; cigarette volumes are declining (-1.5% in 2025), concentrating revenue risk.
Relevance 90·Dependency 55·Confidence 97
Source evidence
“led by Marlboro, the world’s best-selling international cigarette, which accounted for approximately 43% of our total 2025 cigarette shipment volume”
U.S. Dollar
Currency Exposure
PMI conducts business primarily in local currencies but reports in USD; FX fluctuations and capital controls materially affect revenues, EPS and cash flows.
Relevance 88·Dependency 80·Confidence 94
Source evidence
“We conduct our business primarily in local currency and, for purposes of financial reporting, the local currency results are translated into U.S. dollars”
Tobacco leaf and non-tobacco raw materials
Supplier Dependency
Cost of sales primarily consists of tobacco leaf, non-tobacco raw materials, labor and manufacturing, shipping, and third-party device electronics manufacturing.
Relevance 80·Dependency 85·Confidence 90
Source evidence
“Our cost of sales consists primarily of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost of devices produced by third-party electronics manufacturing service providers.”
U.S. FDA authorizations (MRTP, PMTA)
Regulatory Exposure
FDA authorized General snus, ZYN nicotine pouches, and IQOS versions — first-ever authorizations in their categories; U.S. commercialization depends on FDA regulatory pathway.
Relevance 80·Dependency 70·Confidence 92
Source evidence
“the U.S. Food and Drug Administration (the "FDA") has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories.”
WHO Framework Convention on Tobacco Control
Regulatory Exposure
WHO/FCTC reports and proposals could lead to restrictions on SFP availability and information access in current or future markets, with potential material adverse effect on financial results and growth.
Relevance 80·Dependency 55·Confidence 90
Source evidence
“A significant factor influencing these developments are reports issued by the World Health Organization (the "WHO”) and Framework Convention on Tobacco Control (the "FCTC")”
Rothmans, Benson & Hedges (Canada)
Legal Exposure
CCAA resolution requires RBH, ITL, JTIM to pay CAD 32.5B global settlement; PMI recorded $2,316M impairment of its RBH equity investment in 2024; allocation unresolved.
Relevance 75·Dependency 60·Confidence 92
Source evidence
“PMI evaluated its investment in RBH for potential impairment and concluded that the estimated fair value of its investment in RBH was lower than its carrying value.”
US Dollar
Currency Exposure
Highly inflationary accounting in Argentina, Egypt, Turkey, Lebanon remeasures monetary items to USD, producing remeasurement losses of $(26)M in 2025.
Relevance 75·Dependency 50·Confidence 90
Source evidence
“monetary assets and liabilities denominated in local currencies are remeasured to the U.S. Dollar at each balance sheet date, with remeasurement gains and losses recognized in consolidated statement of earnings.”
Elevated inflation raises direct materials, wages, energy, transportation, logistics and financing costs and can reduce consumer demand if prices cannot fully offset.
Relevance 72·Dependency 55·Confidence 92
Source evidence
“A sustained period of elevated inflation across the markets in which we operate could result in higher operating and financing costs and lead to reduced demand for our products.”
PMI relies exclusively on KT&G smoke-free devices/consumables outside South Korea under a 15-year agreement, and plans joint US PMTA submissions for KT&G heat-not-burn products.
Relevance 70·Dependency 40·Confidence 90
Source evidence
“the partners plan to work on a PMTA submission for review by the U.S. FDA, in accordance with the memorandum.”
Illicit trade and counterfeiting
Competitive Exposure
Counterfeit cigarettes and non-compliant/illicit smoke-free products undermine revenues and the reputation of SFPs; Marlboro most counterfeited brand.
Relevance 68·Dependency 50·Confidence 90
Source evidence
“our revenues may be materially adversely affected by counterfeiting, contraband, cross-border purchases, non-tax-paid volume produced by local manufacturers and other non-compliant or illicit cigarettes or smoke-free products.”
Capital controls and currency constraints in Russia (and Argentina) restrict ability to settle FX imports and pay dividends, increasing devaluation risk.
Relevance 65·Dependency 50·Confidence 85
Source evidence
“In a number of jurisdictions, including Argentina and Russia, we are impacted by various capital controls and/or foreign currency exchange constraints”
Foreign-currency denominated debt and derivatives are subject to FX fluctuation primarily between the Euro and US Dollar, impacting debt levels and deleveraging pace.
Relevance 65·Dependency 45·Confidence 90
Source evidence
“Foreign currency denominated debt and the majority of our $50 billion gross notional amount of derivative financial instruments are subject to foreign currency exchange rates fluctuation, primarily between the Euro and U.S. Dollar”
U.S. FDA PMTA
Regulatory Exposure
KT&G heat-not-burn products selected for US commercialization require FDA PMTA review per the MOU.
Relevance 60·Dependency 45·Confidence 85
Source evidence
“Thereafter, the partners plan to work on a PMTA submission for review by the U.S. FDA, in accordance with the memorandum.”
Altria Group, Inc.
Competitive Exposure
Named competitor; PMI ended the U.S. IQOS commercial relationship with Altria in 2022 and holds full U.S. IQOS rights since April 30, 2024.
Relevance 60·Dependency 25·Confidence 92
Source evidence
“we hold the full rights to commercialize IQOS in the U.S. after reaching an agreement to end our U.S. commercial relationship covering IQOS with Altria Group, Inc. in 2022”
PMI paid ~$0.8B disputed supplemental heated tobacco tax surcharge in Germany, a cash flow and tax exposure for the heated tobacco business there.
Relevance 55·Dependency 35·Confidence 90
Source evidence
“the disputed supplemental tax surcharge on heated tobacco products in Germany of approximately $0.8 billion”